corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen.

corporate presentation
3
FDA-approved indications
25,000+
patients treated through July 2022
$535M
annual net revenues (2021)
$201M
annual R&D investments (2021)
4
phase 3 trials in new indications
view all

latest filings

date filing type filing download
September 30, 2022 4 Statement of Changes in Beneficial Ownership
September 26, 2022 4 Statement of Changes in Beneficial Ownership
September 19, 2022 4 Statement of Changes in Beneficial Ownership
September 13, 2022 4/A Amended Statement of Changes in Beneficial Ownership
September 12, 2022 4 Statement of Changes in Beneficial Ownership
September 07, 2022 4 Statement of Changes in Beneficial Ownership
September 06, 2022 4 Statement of Changes in Beneficial Ownership
September 06, 2022 4 Statement of Changes in Beneficial Ownership
September 06, 2022 4 Statement of Changes in Beneficial Ownership
September 06, 2022 4 Statement of Changes in Beneficial Ownership
September 06, 2022 4 Statement of Changes in Beneficial Ownership
August 04, 2022 4 Statement of Changes in Beneficial Ownership
August 03, 2022 4 Statement of Changes in Beneficial Ownership
August 03, 2022 4 Statement of Changes in Beneficial Ownership
August 03, 2022 4 Statement of Changes in Beneficial Ownership
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.